期刊文献+

治疗相关高血压与血管内皮生长因子受体酪氨酸激酶抑制剂治疗转移性肾细胞癌疗效的关系 被引量:4

Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma
收藏 分享 导出
摘要 目的:探讨转移性肾细胞癌( mRCC)患者接受血管内皮生长因子受体酪氨酸激酶抑制剂( VEGFR?TKIs)治疗过程中出现高血压与疗效之间的关系。方法回顾性分析2006年1月至2014年1月中国医学科学院肿瘤医院收治的155例mRCC患者的临床资料,所有患者均一线接受VEGFR?TKIs治疗,其中一线接受舒尼替尼治疗69例,帕唑帕尼治疗14例,索拉非尼治疗51例,法米替尼治疗21例。结果155例mRCC患者在治疗过程中,出现高血压98例(63.2%),其中1度9例(5.8%),2度54例(34.8%),3度35例(22.6%),无4度高血压患者。155例mRCC患者经VEGFR?TKIs治疗后是否发生治疗相关高血压与患者的年龄和纪念斯隆?凯特琳癌症中心分级有关(均P<0.05),而与患者的性别、是否行肾切除、T分期、转移部位数目、有无肺转移、是否接受舒尼替尼治疗无关(均P>0.05)。全组患者的治疗有效率为43.2%(67/155),中位无进展生存时间(PFS)为12.0个月,中位总生存时间(OS)为36.2个月。血压正常和高血压患者的有效率分别为26.3%(15/57)和53.1%(52/98),差异有统计学意义(P=0.001)。血压正常和高血压患者的中位PFS分别为7.1和13.8个月,差异有统计学意义(P=0.032)。1度、2度、3度高血压患者的有效率分别为33.3%(3/9)、51.9%(28/54)和60.0%(21/35),差异有统计学意义(P=0.006)。血压正常、1度、2度、3度高血压患者的中位PFS分别为7.1、9.7、12.0和19.5个月,差异有统计学意义( P=0.039)。单因素和多因素分析均显示,治疗相关高血压是影响VEGFR?TKIs治疗mRCC患者疗效的重要因素。结论在接受VEGFR?TKIs治疗的mRCC患者中,出现治疗相关高血压可能是药物治疗有效的预测因素。 Objective Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR?TKIs) are widely used for the treatment of metastatic renal cell carcinoma (mRCC). The aim of this study was to investigate the association between treatment-related hypertension and the therapeutic efficacy of VEGFR?TKIs. Methods Clinical data of 155 mRCC patients treated with VEGFR-TKIs at the Cancer Hospital of Chinese Academy of Medical Sciences from 2006 to 2014 were retrospectively analyzed. All patients received first-line TKI therapy. Among them, 69 patients were treated with sunitinib, 14 cases with pazopanib, and 51 cases with fazotinib. Kaplan-Meier curves were used to evaluate the survival of the patients. Results The median survival for the whole group ( n=155) was 36. 2 months. Among the 98 (63.2%) patients who developed hypertension, 9 patients (5.8%) were evaluated as gradeⅠ, 54 (34.8%) as grade Ⅱ and 35 (22.6%) as gradeⅢ, and there was no patient with gradeⅣhypertension. The occurrence of TKI-related hypertension was correlated with age and MSKCC score (P〈0.05), while not significantly correlated with gender, nephrectomy, T stage, number of metastases, lung metastasis or sunitinib treatment (P〈0.05 for all). For the whole group (n=155), the therapeutic efficacy rate was 43.2% (67/155), the median progression-free survival (PFS) was 12.0 months, and the median overall survival (OS) was 36.2 months. The response rate (RR) was 26.3% (15/57) in patients with normal blood pressure and 53.1%(52/98) in patients with hypertension (P=0.001). The median PFS was 7.1 months in the cases with normal blood pressure and 13.8 months in patients with hypertension (P=0.032). The response rates were 33.3% (3/9), 51.9% (28/54) and 60.0% (21/35) in patients with grade Ⅰ, Ⅱ and Ⅲ hypertension (P=0.006). The median PFS was 7.1, 9.7, and 12.0 and 19.5 months in patients with normal blood pressure, and patients with grade Ⅰ,
作者 宋岩 杜春霞 张雯 孙永琨 杨林 崔成旭 依荷芭丽·迟 周爱萍 王金万 孙燕 Song Yan, Du Chunxia, Zhang Wen, Sun Yongkun, Yang Lin, Cui Chengxu, Chi Yihebali, Zhou Aiping, Wang Jinwan, Sun Yan( Department of Medical Oncology, National Cancer Certer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China )
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2016年第9期698-702,共5页 Chinese Journal of Oncology
关键词 肾细胞 高血压 受体 血管内皮生长因子 酪氨酸激酶抑制剂 治疗结果 预后 Carcinoma,renal cell Hypertension Receptor,vascular endothelial growth factor Tyrosine kinase inhibitor Treatment outcome Prognosis
作者简介 通信作者:周爱萍.Email:zhouap1825@126.com
  • 相关文献

参考文献13

  • 1MekhailTM, Abou-JawdeRM, BoumerhiG, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma[J]. J Clin Oncol, 2005, 23(4):832-841. DOI:10.1200/JCO.2005.05.17. 被引量:1
  • 2ChoueiriTK, HutsonTE, BukowskiRM, et al. Evolving role of pegylated interferons in metastatic renal cell carcinoma[J]. Expert Rev Anticancer Ther, 2003, 3(6):823-829. DOI:10.1586/14737140.3.6.823. 被引量:1
  • 3MotzerRJ, HutsonTE, TomczakP, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27(22):3584-3590. DOI:10.1200/JCO.2008.20.1293. 被引量:1
  • 4McDermottDF, ReganMM, ClarkJI, et al. Randomized phase Ⅲ trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2005, 23(1):133-141. DOI:10.1200/JCO.2005.03.206. 被引量:1
  • 5MotzerRJ, HutsonTE, TomczakP, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2):115-124. DOI:10.1056/NEJMoa065044. 被引量:1
  • 6EscudierB, EisenT, StadlerWM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2):125-134. DOI:10.1056/NEJMoa060655. 被引量:1
  • 7RiniBI, TamaskarI, ShaheenP, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib[J]. J Natl Cancer Inst, 2007, 99(1):81-83. DOI:10.1093/jnci/djk008. 被引量:1
  • 8ZhuX, StergiopoulosK, WuS. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis[J]. Acta Oncol, 2009, 48(1):9-17. DOI: 10.1080/02841860802314720. 被引量:1
  • 9van HeeckerenWJ, OrtizJ, CooneyMM, et al. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?[J] J Clin Oncol, 2007, 25(21):2993-2995. 被引量:1
  • 10RiniBI. Biomarkers: hypertension following anti-angiogenesis therapy[J]. Clin Adv Hematol Oncol, 2010, 8(6):415-416. 被引量:1

同被引文献9

引证文献4

二级引证文献14

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏